The American Academy of Family Physicians confirms that oral doses of 1,000 to 2,000 mcg daily can correct both anemia and neurologic symptoms in most deficient patients
Our approach is often a two-step process
Tirzepatide receptor pharmacology and predicted receptor occupancy GIPR-forward dual-incretin design, cAMP-biased GLP-1R with low beta-arrestin, GCGR negative control (EC50 329 nM)
These applications remain speculative pending human research, but the biological plausibility is strong
A brand-new 2024 pilot gave two healthy adults up to 20 mg intravenously for two days zero side effects, normal blood tests, heart, liver, kidney, and thyroid markers all fine